Multiple sclerosis (5)

carpal tunnel syndrome (3)

atherogenic index of plasma (2)

electrophysiology (2)

Glutamate (2)

Inflammation (2)

MOGAD (2)

Myelin oligodendrocyte glycoprotein (2)

Obesity (2)

remnant cholesterol (2)

semaphorin 3A (2)

semaphorin 3F (2)

semaphorin 4A (2)

semaphorin 4D (2)

semaphorin 7A (2)

Adherence (1)

adipose tissue thickness (1)

Albumin (1)

albumin | COVID-19 | Fibrinogen | fibrinogen/albumin ratio (1)

Amyloid (1)

Ankylosing spondylitis (1)

anthropometry (1)

associated disease (1)

ataxia (1)

atherogenic index (1)

Atherogenic index of plasma (1)

atherogenic index of plasma | carpal tunnel syndrome | electrophysiology | remnant cholesterol (1)

atypical demyelinating diseasesi MOGAD (1)

atypical demyelinating diseasesi MOGAD | MOG | Myelin oligodendrocyte glycoprotein | myelin oligodendrocyte glycoprotein antibody associated disease (1)

Azathioprine (1)

Biomarker (1)

Body mass index (1)

calcification (1)

Calcium (1)

Carpal tunnel syndrome (1)

cerebrovascular disease | Fabry disease | renal insufficiency (1)

Choroid plexus (1)

Cladribine (1)

Cladribine | Disease-modifying therapies (DMTs) | Expanded disability status scale (EDSS) | Fingolimod | Hepatotoxicity | Liver function tests (LFTs) | Relapsing-remitting multiple sclerosis (RRMS) | Transaminases | Treatment transition | Washout period (1)

diagnostic algorithm (1)

diagnostic delay (1)

Differential diagnosis (1)

Disability (1)

discrimination (1)

Disease activity (1)

Disease-modifying therapies (DMTs) (1)

Efficacy (1)

Excitotoxicity (1)

Excitotoxicity | Glutamate | Ischemia–reperfusion | tDCS (1)

exome sequencing (1)

Expanded disability status scale (EDSS) (1)

Fabry disease (1)

familial (1)

Fibrinogen (1)

Fibrinogen/Albumin ratio (1)

Fingolimod (1)

Follow-on drug (1)

gender (1)

Generic fingolimod (1)

genetic (1)

genetics (1)

GLA (1)

Glycogen storage disease type V | McArdle disease | Myophosphorylase | PYGM (1)

Hepatotoxicity (1)

heterogeneity (1)

Immunoglobulin IgG index (1)

Ischemia-reperfusion (1)

identification (1)

index of suspicion (1)

ischemic stroke (1)

ischemic stroke | semaphorin 3A | semaphorin 3F | semaphorin 4A | semaphorin 4D | semaphorin 7A (1)

late-onset Pompe disease (1)

ligamentum flavum (1)

lipid profile (1)

Lipid profile (1)

Liver function tests (LFTs) (1)

Median nerve (1)

Migraine with aura (1)

migraine without aura (1)

MOG (1)

Molecular screening (1)

MS (1)

myasthenia gravis (1)

myasthenia gravis | semaphorin 3A | semaphorin 3F | semaphorin 4A | semaphorin 4D | semaphorin 7A (1)

myelin oligodendrocyte glycoprotein antibody associated disease (1)

myelin oligodendrocyte glycoprotein antibody disease (1)

N-methyl-d-aspartate receptor (1)

Obesity | Restless Legs Syndrome | Subcutaneous Fat (1)

olfactory dysfunction (1)

Oligoclonal band number (1)

optic ne uritis (1)

optic neuritis (1)

osteopontin (1)

outcome (1)

polyneuropathy (1)

Rat (1)

Real-world data (1)

Relapsing-remitting multiple sclerosis (RRMS) (1)

Restless Legs Syndrome (1)

Retinal nerve fiber layer (1)

Rituximab (1)

Safety (1)

Satisfaction (1)

SD-OCT (1)

Sniffin' Sticks test (1)

Subcutaneous Fat (1)

tDCS (1)

threshold (1)

Transaminases (1)

Transcranial direct current stimulation (1)

Traumatic brain injury (1)

treatment (1)

Treatment (1)

Treatment transition (1)

Turkey (1)

Washout period (1)

whole&#8208 (1)